Amycretin: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •6 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (4 countries listed)
Risk Assessment
Amycretin is not approved by any regulatory authority. Phase 1b/2a and Phase 2 trials completed; Phase 3 planned for 2026. Full safety profile not established.
In Phase 1b/2a, nausea occurred in 82%, vomiting in 53%, and diarrhea in 41% of participants. While mostly mild to moderate, these rates are among the highest in the dual-agonist class.
The GLP-1 receptor agonist component carries the class warning for thyroid C-cell tumors. Contraindicated in patients with MTC or MEN2.
Both GLP-1 and amylin agonists carry pancreatitis risk. Dual mechanism may warrant enhanced monitoring.
The substantial weight loss (up to 24.3% at 36 weeks) increases the risk of cholelithiasis and cholecystitis.
33% of Phase 1b/2a participants discontinued. While most discontinuations were unrelated to AEs, this rate warrants monitoring in larger trials.
⚠️Important Warnings
- •INVESTIGATIONAL AGENT: Amycretin is not approved by any regulatory authority. It should only be used within approved clinical trials.
- •EXPECTED GLP-1 CLASS WARNING: Amycretin is expected to carry the thyroid C-cell tumor warning. Do not use in patients with MTC or MEN2 history.
- •GI adverse events are very common (nausea 82%, vomiting 53%, diarrhea 41% in Phase 1b/2a). Most are mild to moderate. Maintain adequate hydration.
- •Do not use during pregnancy. Both GLP-1 and amylin agonists should be discontinued before planned conception.
- •No cardiovascular outcomes data are available. Long-term cardiovascular safety has not been established.
- •Dual GLP-1/amylin activation produces additive gastric emptying delay. Use caution with co-administered oral medications.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Phase 1b/2a and Phase 2 completed. Phase 3 planned for 2026. Not FDA-approved. |
| European Union | Investigational | Not EMA-approved. Regulatory pathway anticipated following Phase 3. |
| United Kingdom | Investigational | Not MHRA-approved. No regulatory submission. |
| Canada | Investigational | Not Health Canada-approved. No regulatory submission. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
0View community protocolsCritical Safety Information#
Amycretin is an investigational first-in-class dual GLP-1/amylin receptor agonist. Safety data are derived from Phase 1 (144 participants), Phase 1b/2a (125 participants), and Phase 2 T2D (448 participants) trials, with maximum treatment duration of 36 weeks.
Investigational Status#
Amycretin is in early-mid stage development:
- Phase 1b/2a (obesity): Completed, results published in The Lancet
- Phase 2 (T2D): Completed
- Phase 3: Planned for both obesity and T2D in 2026
- NDA: Not filed; regulatory approval several years away
- Dual formulation: Both SC and oral in development
High GI Adverse Event Rates#
The dual GLP-1/amylin mechanism produces additive GI effects:
Phase 1b/2a Rates#
| Adverse Event | Rate |
|---|---|
| Nausea | 82% |
| Vomiting | 53% |
| Diarrhea | 41% |
| Decreased appetite | Very common |
These rates are among the highest reported in the dual-agonist class (CagriSema: 79.6% overall GI; tirzepatide: ~40-50%). However:
- Most events were mild to moderate
- Events peaked during up-titration and diminished
- The Phase 1b/2a was an early study; Phase 3 with optimized dose escalation may show lower rates
Study Discontinuation#
The 33% discontinuation rate in Phase 1b/2a warrants attention:
- 59% of discontinuations were unrelated to adverse events (consent withdrawal, protocol deviations)
- The AE-related discontinuation rate was lower than the headline number
- Single-center Phase 1b/2a studies often have higher discontinuation rates than multisite Phase 3 trials
GLP-1 and Amylin Agonist Class Risks#
Thyroid C-Cell Tumors#
GLP-1 receptor agonists carry a class-wide boxed warning. Amycretin is expected to carry similar warnings for MTC/MEN2.
Pancreatitis#
Both GLP-1 and amylin agonists are associated with pancreatitis risk. The dual mechanism may warrant enhanced monitoring.
Gallbladder Disease#
Up to 24.3% weight loss at 36 weeks significantly increases gallstone risk.
Acute Kidney Injury#
The high GI event rates (82% nausea, 53% vomiting) increase dehydration risk and potential AKI.
Regulatory and Legal Status#
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (FDA) | Investigational | Phase 3 planned 2026 |
| European Union (EMA) | Investigational | No regulatory submission |
| United Kingdom (MHRA) | Investigational | No regulatory submission |
| Canada (Health Canada) | Investigational | No regulatory submission |
At-Risk Populations#
Patients with MTC or MEN2 History#
Expected absolute contraindication.
Pregnant and Breastfeeding Women#
Both GLP-1 and amylin agonists carry pregnancy risks.
Patients with Severe GI Disease#
The additive gastric emptying effects from dual GLP-1/amylin activation may be poorly tolerated.
Patients on Insulin#
Dual GLP-1/amylin agonism with insulin requires careful dose management.
Risk Mitigation#
- Use only within approved clinical trials
- Screen for MTC/MEN2 history
- Follow dose escalation schedule to minimize GI events
- Maintain adequate hydration (especially with high vomiting rates)
- Monitor for pancreatitis and gallbladder symptoms
- Adjust insulin doses when initiating amycretin
Related Reading#
Frequently Asked Questions About Amycretin
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.